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Abstract
Background:  Active tuberculosis (TB) is common among HIV-infected persons living in
tuberculosis endemic countries, and screening for tuberculosis (TB) is recommended routinely.
We sought to determine the role of chest x-ray and sputum culture in the decision to treat for
presumptive TB using active case finding in a large cohort of HIV-infected patients.
Methods: Ambulatory HIV-positive subjects with CD4 counts ≥ 200/mm3 entering a Phase III TB
vaccine study in Tanzania were screened for TB with a physical examination, standard interview,
CD4 count, chest x-ray (CXR), blood culture for TB, and three sputum samples for acid fast bacillus
(AFB) smear and culture.
Results: Among 1176 subjects 136 (12%) were treated for presumptive TB. These patients were
more frequently male than those without treatment (34% vs. 25%, respectively; p = 0.049) and had
lower median CD4 counts (319/μL vs. 425/μL, respectively; p < .0001). Among the 136 patients
treated for TB, 38 (28%) had microbiologic confirmation, including 13 (10%) who had a normal
CXR and no symptoms. There were 58 (43%) treated patients in whom the only positive finding
was an abnormal CXR. Blood cultures were negative in all patients.
Conclusion: Many ambulatory HIV-infected patients with CD4 counts ≥ 200/mm3 are treated for
presumptive TB. Our data suggest that optimal detection requires comprehensive evaluation,
including CXR and sputum culture on both symptomatic and asymptomatic subjects.
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Background
Tuberculosis (TB) is the major cause of death from AIDS
in most areas of the developing world [1,2]. The high
mortality of HIV-associated TB reflects multiple factors,
including lack of access to care, delayed or missed diagno-
sis of TB and acceleration of HIV infection [2-5]. Active TB
is considered an indication for anti-retroviral therapy
(ART) in HIV-infected persons with CD4 counts <350, but
treatment of co-infection may be complicated by drug
interactions and by immune reconstitution syndrome
[6,7]. For these reasons screening for active TB is recom-
mended for patients with HIV living in TB-endemic
regions. However, only limited data are available on the
relative sensitivity of different methods of screening for
active TB among HIV-infected patients with CD4 counts ≥
200. The World Health Organization (WHO) recom-
mends screening for TB prior to ART based on symptoms
followed by sputum acid fast bacillus (AFB) smear; chest
x-ray (CXR) and sputum culture are not routine in their
method [6,8].
This report describes our experience applying a compre-
hensive screening program (including both CXR and spu-
tum culture) to both symptomatic and asymptomatic
ambulatory HIV-infected subjects with CD4 counts ≥ 200
being evaluated for a TB vaccine trial in Tanzania. With
this approach, 12% of those screened were treated for pre-
sumptive TB based on the local standards of care. Fewer
than half of these cases would have been detected by
symptoms and AFB smear alone; many were only detected
by CXR and some cases only by sputum culture. These
observations have major implications for HIV programs.
Methods
Study subjects and protocol
Subjects are screened for HIV and tuberculosis as part of
the DarDar (Dartmouth Medical School-Dar es Salaam)
Study, a Phase III trial of a prime-boost vaccine strategy for
the prevention of HIV-associated TB (prime = childhood
BCG, boost = multiple dose whole cell inactivated myco-
bacterial vaccine) [9] being conducted in Tanzania.
Ambulatory HIV-infected subjects age ≥ 18 years in appar-
ent good health are referred from HIV voluntary coun-
seling and testing (VCT) centers in Dar es Salaam or by
other study subjects. Informed consent was obtained from
all subjects.
Eligibility requirements for the vaccine study include two
positive ELISA antibody tests for HIV, CD4 count ≥ 200/
mm3 and BCG scar. All subjects meeting these criteria
were evaluated for active TB by symptoms, chest x-ray and
microbiology. The latter involved collecting three expec-
torated sputum samples for AFB smear and culture.
Patients were instructed to cough deeply and were encour-
aged to produce one spot sample and bring two subse-
quent first morning samples; sputum induction was not
used. A single 10 mL mycobacterial blood culture was
processed using the MB/BacT automated system (bioMer-
ieux, Inc, Durham, NC, USA). A tuberculin skin test (TST)
was performed with 0.1 mL intradermal RT-23 (State
Serum Institute, Copenhagen) and read at 48–72 hrs as
mm induration in the transverse diameter.
For the purposes of this report symptoms of TB were
defined as either cough or fever for ≥ 2 weeks or both.
Chest x-rays were read by the principal radiologist at the
university teaching hospital, Muhimbili University Col-
lege of Health Sciences (MUCHS); the requisition indi-
cated whether the patient has suspect TB. An abnormal x-
ray is defined as the presence of a focal infiltrate, cavity
formation, hilar adenopathy, or a miliary pattern. The
decision to treat for suspect TB was made by study physi-
cians in collaboration with physicians from the Tanzania
National Tuberculosis and Leprosy Program (NTLP)
based on clinical, laboratory and/or radiologic features
consistent with TB. CXR and AFB smear results were avail-
able for these decisions and patients were typically
assessed for radiologic response to a 10 day course of anti-
biotic therapy for community acquired pneumonia before
the decision to treat for TB. Other than blood culture,
there was no detailed testing for extrapulmonary TB
among the subjects described in the present report. Fol-
low-up data on whether the subject started treatment as
recommended was obtained from the NTLP.
In the DarDar Study, the endpoints of definite or probable
TB are based on strict definitions (Table 1) which are
applied by a panel of three experts who review the clinical,
radiologic and microbiologic data. Among subjects with-
out microbiologic confirmation, classification as definite
or probable TB requires 6–8 months of follow-up to deter-
mine the response to TB treatment. The purpose of this
report is to provide data on the basis for an initial clinical
decision to treat for TB in accordance with local standards
of care. The subjects treated for TB in the present report
were discharged from the study without further follow-up
and, consequently, we cannot confirm that all the treated
patients (e.g, patients with symptoms alone) would meet
strict research-oriented criteria for TB.
The research protocol was approved by the Ethics Com-
mittee of the Muhimbili University College of Health Sci-
ences and the Dartmouth Committee for the Protection of
Human Subjects.
Laboratory methods
Serum samples are tested using 2 different HIV ELISA
methods: Vironostika HIV Uni-Form II Ag/Ab (BioMer-
ieux, Boxtel, The Netherlands) and Vironostika HIV Uni-
Form II Plus O (BioMerieux, Boxtel, The Netherlands).BMC Infectious Diseases 2008, 8:32 http://www.biomedcentral.com/1471-2334/8/32
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Subjects reactive on both assays are considered HIV-
infected. Blood is collected in EDTA tubes for enumera-
tion of CD4 cells by FASCount (BD Biosciences, Franklin
Lakes, NJ) after staining with monoclonal antibodies [10].
Sputum samples are examined by direct microscopy using
auramine-rhodamine staining with confirmation of posi-
tives by Ziehl Neelsen AFB staining. Sputum samples are
also decontaminated in 2% NaOH for 30 minutes, con-
centrated by centrifugation at 3000 g, examined again by
microscopy and cultured on Lowenstein Jensen slants for
10 weeks at 37°C. Sputum culture contamination rates
were approximately 1% during the period of this report.
Blood is cultured using the MB/BacT method according to
manufacturer's instructions (Bio-Merieux, Lyon, France).
Characteristic slow-growing mycobacteria are presump-
tively identified as M. tuberculosis. Putative M. tuberculosis
isolates are shipped to Dartmouth to confirm M. tubercu-
losis  complex by DNA probe testing (AccuProbe, Gen-
Probe, San Diego, CA)
Statistical analysis
Standard descriptive statistical methods are used to deter-
mine median, interquartile range and the percent of sub-
jects with particular characteristics. All p-values are based
on Fisher's exact test or Wilcoxon test, as appropriate, and
are 2-sided. A p-value < 0.05 is considered statistically sig-
nificant.
Results
Between September 2001 and March 2004 a total of 1794
ambulatory subjects were screened for the DarDar Study.
Based on a CD4 count ≥ 200/mm3 and presence of a BCG
scar, 1176 subjects proceeded to comprehensive evalua-
tion for active TB (Figure 1). Among these, 136 (12%)
subjects were considered ineligible to continue in the
Study based on suspect TB and were referred to the NTLP
for TB treatment. Figure 1 summarizes the basis for the
treatment of presumptive TB among CD4 eligibles. Fol-
low-up data were available on 113 (83%) indicating that
all were treated for TB; data on completion of, or response
to, treatment were not available since these subjects were
ineligible for the main study and did not have detailed
follow-up.
Table 2 summarizes the characteristics of patients with
and without TB treatment. Patients with TB treatment
were more often male, had a lower median CD4 count
and a higher rate of both prior TB and a TST ≥ 5 mm. Table
3 summarizes the diagnostic contribution of symptoms,
x-ray and microbiology on 136 subjects with TB treat-
Basis for TB treatment in HIV-infected subjects with CD4  counts ≥ 200/mm3 Figure 1
Basis for TB treatment in HIV-infected subjects with 
CD4 counts ≥ 200/mm3. Sputum microbiology was posi-
tive in 1 patient with symptoms, 10 with abnormal chest x-
ray and 14 with both findings. See Table 2 for details.
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Table 1: Definitions of TB for the DarDar Study
Definite TB 1. One or more sputum cultures positive for Mycobacterium tuberculosis (MTB) with ≥ 10 colony forming units (CFU); or,
2. Two or more sputum cultures with 1–9 CFU of MTB (indeterminate MTB culture); or,
3. Two or more positive sputum smears for acid fast bacilli (AFB) *; or,
4. One or more cultures for MTB from the blood or other sterile body site.
Probable TB 1. Positive chest x-ray plus either
a. one positive sputum AFB smear, or,
b. one indeterminate MTB culture result; or,
2. Clinical symptoms/signs plus either
a. one positive sputum AFB smear, or,
b. an indeterminate MTB culture result; or,
3. Clinical symptoms/signs and a positive x-ray plus a response to anti-TB therapy; or,
4. One positive sputum AFB smear from a sterile site plus clinical symptoms/signs of tuberculosis; or,
5. Caseous necrosis on a tissue biopsy.
AFB, acid fast bacillus; CFU, colony forming units; MTB, Mycobacterium tuberculosis; TB, tuberculosis.
* a positive AFB smear is defined as ≥ 2 acid-fast organisms per 100 oil immersion fieldBMC Infectious Diseases 2008, 8:32 http://www.biomedcentral.com/1471-2334/8/32
Page 4 of 7
(page number not for citation purposes)
ment. An abnormal chest x-ray in the absence of symp-
toms was the basis for treatment in 68 (50%) cases; 10 of
these cases had positive microbiology leaving 58 (43%)
cases in which treatment was based on the chest x-ray
alone. Symptoms plus an abnormal chest x-ray resulted in
treatment for 44 (32%) of cases. Symptoms without a
positive chest x-ray resulted in treatment for 11 (8%) of
cases.
Among 124 subjects who produced sputum samples 106
were submitted for AFB stain and culture and 18 for AFB
stain only. A total of 38 (31%) of 124 tested subjects had
a positive AFB smear or mycobacterial culture; these sub-
jects meet a study definition of definite or probable TB
(Table 1). Positive sputum microbiology was present in
14 (32%) of 44 subjects tested with both symptoms and
an abnormal chest x-ray and in 1 (20%) of 5 subjects
tested with symptoms only (p = 0.7). DNA probes were
positive for M. tuberculosis complex on all 36 isolates
tested. Blood cultures were negative on all subjects.
In 13 (10%) of 136 cases of TB the diagnosis was estab-
lished by sputum microbiology alone in patients with no
symptoms and negative chest x-rays. Ten of these cases of
"subclinical TB" were reported previously [3]. These
patients represent 34% (13 of 38) of all subjects with pos-
itive sputum microbiology.
Discussion
We have shown that 12% of ambulatory HIV-infected
patients in Tanzania undergoing comprehensive screen-
ing are treated for presumptive and previously undiag-
nosed active TB. Our results suggest that the optimal
diagnosis of TB in this setting requires assessment of both
symptomatic and asymptomatic HIV-positive patients
using chest x-ray and sputum culture, an observation that
differs from consensus international recommendations
and has obvious implications for the resources needed to
conduct effective and optimal treatment of persons with
HIV infection. Confirmation of this preliminary finding
will be available when our expert panel completes classi-
fication of TB endpoints among the eligible subjects in the
trial, including independent review of chest x-rays and
response to treatment.
An abnormal chest x-ray in the absence of symptoms was
the most common basis for the suspicion of TB. This find-
ing differs from an initial report from Botswana in which
an abnormal chest x-ray was very rare among HIV-
infected subjects with no symptoms of TB [11] and a study
in South Africa where symptom-based screening was
effective [12]. However, our results and those of other
recent surveys [13,14] including a more recent report from
Botswana [15] suggest that the chest x-ray is important in
screening and that the standard recommendation to
Table 3: Basis for TB treatment among 1176 HIV-infected subjects with CD4 ≥ 200/mm3
Category No. (%) Microbiology*
AFB positive only Culture positive only Both positive Any positive
No TB 1040 (88%)
TB 136 (12%) 2/124 (2%) 23/106 (22%) 13/106 (12%) 38/136 (28%)
Symptoms (fever or cough ≥ 2 wks) 11/136 (8%) 0/5 (0%) 1/4 (25%) 0/4 (0%) 1/5 (20%)
Abnormal chest x-ray 68/136 (50%) 0/62 (0%) 7/54 (13%) 3/54 (6%) 10/62 (16%)
Symptoms and chest x-ray 44/136 (32%) 2/44 (5%) 6/35 (17%) 6/35 (17%) 14/44 (32%)
Microbiology only 13/136 (10%) 0/13 (0%) 9/13 (69%) 4/13 (31%) 13/13 (100%)
AFB = acid fast bacillus.
* Denominators for microbiology represent proportion in each category who had the given test performed (e.g. 124 subjects had AFB smear 
performed but only 106 had sputum culture performed).
Table 2: Characteristics of HIV-infected patients with CD4 ≥ 200 with and without TB treatment
Category TB treatment (N = 136) No TB treatment (N = 1040) p value
Age, median (interquartile range) 35 (30–40) 33 (27–39) <0.05
Female N (%) 90 (66%) 775 (75%) 0.049
CD4, median (interquartile range) 319 (248–483) 425 (310–594) <0.0001
History of TB N (%)* 3/16 (19%) 67/944 (7%) NS
Tuberculin skin test ≥ 5 mm N (%)* 10/14 (71%) 288/904 (31%) 0.003
Tuberculin skin test ≥ 10 mm* 10/14 (71%) 265/904 (29%) 0.002
* Data only collected on the subjects thought initially to be eligible for the trial; all were later deemed ineligible due to presumptive TB.BMC Infectious Diseases 2008, 8:32 http://www.biomedcentral.com/1471-2334/8/32
Page 5 of 7
(page number not for citation purposes)
screen for TB based on symptoms alone may be unreliable
and insensitive in sub-Saharan Africa [16]. Based on our
data, if AFB smear had only been performed on patients
with symptoms, 55 patients would have had an AFB
smear and only 8 of these (6% of all treated cases) would
have been positive and been treated.
Prevalence rates for TB depend on the patient population,
screening methods and TB case definitions employed. The
12% point prevalence of TB treatment in our study com-
pares to rates of 3–12% in other studies among HIV-
infected persons living in TB endemic countries
[12,13,17-22]. A recent study from South Africa using
chest x-ray, sputum culture and a clinical definition cate-
gory for TB found that 11% of subjects in an ART program
had previously undiagnosed TB at baseline and that rates
of incident TB in those on ART for 3 years continued to be
5–10 fold higher than those for HIV-uninfected persons
living in the same region [22].
Microbiologic studies confirmed the diagnosis of TB in
31% of those with suspect disease. Our relatively low rate
of positive sputum cultures for TB might have been influ-
enced by overly vigorous decontamination of sputum
specimens as suggested by our low sputum culture con-
tamination rate of 1%. However, by routinely performing
sputum microbiology in this population, including in
those without symptoms, we were able to identify a
unique group of subjects with "subclinical TB", i.e., active,
culture-positive disease without symptoms (including
study definition symptoms as well as absence of addi-
tional symptoms such as weight loss or fever <2 weeks) or
x-ray findings. A previous report from our study focused
on 10 such patients whom we encountered among the ini-
tial 500 subjects screened; that report also presented
detailed data to eliminate the possibility of false positive
cultures and follow-up data to indicate that the early treat-
ment was associated with a more favorable prognosis than
typically seen with HIV-associated tuberculosis [3]. The 13
patients in the present series comprise 9% of all patients
treated for TB. Rates of subclinical TB might be found to
be even higher if more sensitive liquid based media had
been used for sputum culture [23]. Investigators in
Uganda, India, New York and London have also described
HIV-infected subjects with subclinical forms of TB [7,24-
26]; in some of these studies "subclinical" includes any
active disease without symptoms, regardless of chest x-ray
findings.
Sputum culture not only makes an important contribu-
tion to the diagnosis of both clinical and subclinical TB in
patients with HIV [20,25]. It will also be an increasingly
important TB diagnostic tool for another reason: the
detection and spread of XDR TB in sub-Sarharan Africa
[27]. As we showed previously in Kenya [28] and others
have confirmed [5], blood culture for M. tuberculosis may
make an additional contribution in hospitalized patients
with advanced and symptomatic HIV infection but did
not contribute to detection of TB in ambulatory subjects
with earlier stage HIV infection.
Our overall study is focused on ambulatory HIV-infected
persons with CD4 = 200 residing in an area with endemic
tuberculosis. We believe our subjects are generally repre-
sentative of such patients, although there are potential
sources of bias. Conceivably, persons with subtle or unre-
ported symptoms of TB might have been preferentially
drawn to a TB vaccine trial. Conversely, because all sub-
jects had received BCG at birth, this could have reduced
the rate of active TB. In general populations, BCG immu-
nization does not typically affect adult TB rates [29] and
among HIV-infected persons limited retrospective data is
conflicting [30,31].
Our goal in this report was to describe the frequency and
characteristics of subjects who were judged by TB clini-
cians to require treatment for presumptive TB at the time
of screening. Our evaluations were conducted by trained,
experienced local physicians, supported by expert radio-
logic interpretation, albeit by a single radiologist aware of
the suspicion of TB. In a study from the United States
expert radiologists agreed on chest x-ray suspicion of
tuberculosis in 139 subjects (HIV status not stated)
approximately 70% of the time, and this suspicion
appeared to accurately identify smear negative tuberculo-
sis in 48% of cases [32]. We cannot confirm that all
patients treated for TB without microbiologic confirma-
tion had active disease because they were ineligible for our
vaccine study and did not have follow-up to assess
response to therapy. Current microbiologic methods
often fail to confirm disease in subjects who have classic
TB symptoms with x-ray changes and subsequent radio-
logic and clinical response to therapy for TB. In other pub-
lished series of HIV-associated TB 19–66% of subjects
have met a "clinical" definition of TB with negative micro-
biology [21,33,34].
Conclusion
Our findings reflect the realities of a presumptive TB diag-
nosis in regions endemic for both TB and HIV infection. If
confirmed in the eligible subjects in our trial whose TB
endpoints are classified according to our strict case defini-
tions our findings will have important implications for
ART programs in such environments. First, chest x-ray and
sputum microbiology will identify a significant number of
cases of presumptive TB even among those who deny fever
or cough; treatment of these subclinical cases may reduce
mortality from HIV-associated TB; thus, an effort should
be made to expand availability of these tests in resource
poor regions [3]. Second, with rigorous TB screening asBMC Infectious Diseases 2008, 8:32 http://www.biomedcentral.com/1471-2334/8/32
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many as 12% of ambulatory HIV-infected subjects with
CD4 counts = 200/mm3 will qualify for ART based on the
decision to treat for TB; early ART in these subjects may
reduce mortality [35]. Third, a substantial proportion of
ART eligible subjects will require deferral of single drug
preventive therapy for latent TB while active TB is being
excluded by culture. Finally, these data emphasize the
importance of integrating TB and HIV programs in coun-
tries with high rates of co-infection, of educating clini-
cians about the diverse manifestations of TB in HIV-
infected patients, and of providing optimal methods for
TB diagnosis.
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